ClinicalTrials.gg
Active, not recruitingNCT07623486Updated Jun 8, 2026

Trial of HSK44459 Cream for the Management Plaque Psoriasis

A Phase 1/2 interventional study of HSK44459 Cream and Vehicle in Psoriasis, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
90th of 182
180 · median 171
Started
2026
with 17 others
Phase 1/2
11 of 206
2 open now
Primary completion
2027-03
later than 39 of 65 live
Registered
194th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 90th largest by planned enrollment of the 182 interventional ones that give a count, is one of 18 that started in 2026, is one of 11 in phase 1/2, reaches primary completion later than 39 of the 65 other live ones, and was the 194th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

Phase I

Study Objectives:

  • Primary: Assess the safety and tolerability of HSK44459 cream in 10 healthy adult participants and 10 patients with plaque psoriasis.
  • Secondary: Evaluate the pharmacokinetic (PK) profile of HSK44459 cream in the same populations (healthy adults and plaque psoriasis patients).

Participant Allocation:

- 10 healthy adults and 10 plaque psoriasis patients are enrolled. Participants are randomized to either the HSK44459 cream group (8 per population) or the vehicle (placebo - like) control group (2 per population).

Treatment Schedule:

  • Day 1: Single - dose administration (one application).
  • Days 2-3: Washout period (no medication).
  • Days 4-9: Twice - daily administration.
  • Day 10: One application.

Phase II

Study Objectives:

  • Primary: Conduct a preliminary evaluation of the efficacy of HSK44459 cream in treating plaque psoriasis.
  • Secondary: Assess the safety and tolerability of HSK44459 cream in plaque psoriasis patients.

Evaluate the PK profile of HSK44459 cream in plaque psoriasis patients.

Participant Allocation:

- 160 plaque psoriasis patients are enrolled and randomized in a 1:1:1:1 ratio to four groups: 1% HSK44459 cream (40 patients), 0.3% HSK44459 cream (40 patients), 0.1% HSK44459 cream (40 patients), or vehicle control (40 patients).

Treatment Schedule:

Phase II: The study consists of three phases (screening, treatment, and follow - up)

  • Screening Period (D - 28 to D - 1): Eligible plaque psoriasis patients sign an informed consent form and complete screening assessments to establish baseline data.
  • Treatment Period (W1D1 to W9D1 ± 3 days): After baseline evaluation, eligible patients are randomized. The first dose of the study drug is administered on W1D1, with twice - daily dosing for 8 weeks. Patients return to the study center at W3D1 ± 3, W5D1 ± 3, W7D1 ± 3, W9D1 ± 3, and W11D1 ± 3 for scheduled assessments and procedures.
  • Follow - up Period (W9D1 ± 3 days to W11D1 ± 3 days, within 14 days after the last dose): Adverse events and concomitant medications are collected. A final safety visit (W11D1 ± 3 days) includes additional assessments and procedures.

In summary, this trial aims to comprehensively evaluate HSK44459 cream's potential as a treatment for plaque psoriasis, while also characterizing its safety, tolerability, and PK properties in both healthy individuals and patient populations.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Participants in Phase I Study:

  • Able to communicate effectively with researchers, fully understand the study's purpose and requirements, voluntarily participate in the clinical trial, and sign a written form;
  • Age at screening: 18-45 years (inclusive of boundary values), both male and female are eligible;
  • Weight at screening: ≥50 kg (males), ≥45 kg (females); (BMI) between 19.0-27.0 kg/m² (inclusive of boundary values);
  • At screening and before drug administration, the skin in the target application area has no ulcers, injuries, sunburn, erythema, papules, pigmentation, uneven skin tone, excessive freckles, or abnormal heat. Participants must agree to shave hair from this skin area (if present) to ensure uniform drug application and to distinguish skin conditions (e.g., edema, erythema, papules, increased temperature).
  • The participant (and their partner, if applicable) agrees to have no plans for pregnancy, sperm donation, or egg donation during the study and for 3 months after drug administration. Effective non - pharmacological measures (e.g., complete abstinence, condoms, intrauterine devices, partner sterilization) must be used.

Patients with Psoriasis in Phase I and Phase II Studies:

Demographics:

  • Fully understand the study, voluntarily participate, and sign the informed consent form;
  • Age ≥18 years, gender - unrestricted;
  • Able to understand and complete study - related scales, agree to have photographs taken of the lesion area, and comply with follow - up schedules and other protocol requirements.
  • At screening: ≥50 kg (males), ≥45 kg (females); BMI between 19-27 kg/m² (inclusive of boundary values). Only applicable to Phase I study

Disease - Related:

  • Diagnosed with plaque psoriasis for ≥6 months (as of randomization);
  • Plaque psoriasis has been stable in the past 4 weeks, defined as: no morphological changes or severe disease progression (as judged by the investigator).
  • Both screening visits and baseline assessments meet the criteria for plaque psoriasis, and the following requirements must be satisfied simultaneously:

Body surface area (BSA) of psoriatic lesions: 2%-20% (inclusive of both endpoints, excluding scalp, palms, and soles); Psoriasis Area and Severity Index (PASI): ≥2 (excluding scalp, palms, and soles); Investigator Global Assessment (IGA): ≥2 points.

-The investigator assesses that the participant is suitable for topical treatment.

Contraception Requirements:

During the entire study period (from signing the informed consent form) and for 3 months after the last dose, women of and male participants who have not undergone vasectomy must use effective contraceptive measures. Effective contraceptive measures include: vasectomy, abstinence, intrauterine device (IUD), hormones (oral, patch, ring, injection, implant), and barrier methods (diaphragm, cervical cap, sponge, condom).

Exclusion criteria

Exclusion Criteria:

Healthy Participants in Phase I Study:

  • Those with abnormal results in vital signs, physical examination, laboratory tests (routine blood test, biochemical blood test, coagulation function, routine urine test), chest PA X - ray, abdominal color Doppler ultrasound, etc., and deemed unsuitable to participate in this trial by the investigator;
  • Those with a history of heart - related diseases such as familial hereditary heart disease, ischemic heart disease, heart failure, malignant arrhythmia, etc.; those with a confirmed history of prolongation; those with the following (ECG) findings during the screening period:

    1. QT interval corrected by Fridericia's method (QTcF): > 450 ms for male subjects, > 470 ms for female subjects;
    2. Second - degree or third - degree atrioventricular block;
    3. Bundle branch block;
    4. PR interval ≥ 220 ms; or those with ECG results that are judged by the investigator to be clinically significantly abnormal during the screening period;
  • Those with a history of major diseases in the cardiovascular, respiratory, digestive, urinary, hematological, endocrine, immune, or nervous systems, or those who underwent major surgery within 3 months before the screening period or whose surgical incisions have not fully healed;
  • Those known to be allergic to any component of the drug or formulation, or those with allergic constitutions (e.g., allergic to two or more drugs, foods, or pollens); or those with a history of specific allergies (e.g., asthma, urticaria, eczema, etc.);
  • Those with special dietary requirements and unable to comply with a unified diet;
  • Those who consumed excessive tea, coffee, or caffeinated beverages (on average more than 4 cups per day, 1 cup = 250 mL) within 3 months before the screening; or those who took tea or any food or beverage containing caffeine (e.g., coffee, chocolate, etc.) within 48 hours before the first dosing; or those who do not agree to stop taking tea, coffee, or caffeinated foods or beverages during the trial;
  • Those who ingested a large amount of beverages or foods rich in grapefruit (i.e., pomelo) (e.g., grapefruit, grapefruit juice, grapefruit jam, etc.) within 14 days before the screening; or those who ingested any beverage or food rich in grapefruit (i.e., pomelo) within 48 hours before the first dosing; or those who do not agree to stop drinking any beverage or food rich in grapefruit (i.e., pomelo) during the trial;
  • Those with a history of alcohol abuse within 3 months before the screening, i.e., drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of liquor with 40% alcohol content or 150 mL of wine), or those who cannot abstain from alcohol during the trial, or those with a positive alcohol breath test;
  • Those who smoked more than 5 cigarettes per day (or used an equivalent amount of nicotine - containing products) within 3 months before the screening, or those who cannot refrain from smoking during the trial;
  • Those who donated blood or had blood loss ≥ 400 mL (excluding menstrual blood loss in women) within 3 months before the screening, or plan to donate blood during the study period, or received blood transfusion or used blood products within 3 months before the screening;
  • Those who took any prescription drugs, over - the - counter drugs, Chinese herbal medicines, or health supplements within 14 days before the screening or within 5 half - lives of the drug (whichever is longer);
  • Those who participated in other clinical trials of drugs within 3 months before the screening; or those who plan to participate in other clinical trials during the trial;
  • Those who were vaccinated with a (except influenza vaccine) within 1 month before the screening, or those who plan to be vaccinated with a live vaccine during the trial;
  • Those with a history of drug abuse, drug misuse, or drug dependence, or those with a positive drug abuse screening;
  • Those who have one or more positive test results for virus surface antigen, virus antibody, antibody, and Treponema pallidum antibody during the screening period;
  • Those with a history of fear of needles or blood, difficulty in blood collection, or inability to tolerate venipuncture for blood collection;
  • Pregnant or lactating women; or those with a positive pregnancy test;
  • Those whom the investigator deems to have poor compliance, or those with other factors that make them unsuitable to participate in this trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    HSK44459 Cream

    HSK44459 Cream

    Drug: HSK44459 Cream

  • Placebo comparator
    Vehicle

    Drug: Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Psoriasis Area Severity Index 75 (PASI-75)

    The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The number of participants achieving PASI-75 (defined as a 75% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.

    Time frame: Baseline (Day 1) and Week 8

Secondary outcomes

  1. Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8

    The number of participants achieving "success" in IGA assessment of disease severity at Week 8 is presented (observed data only) for each arm. Success was defined as achievement of an IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.

    Time frame: Baseline (Day 1) and Week 8

  2. Number of Participants Achieving Psoriasis Area Severity Index-90 (PASI-90)

    Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease) \[higher scores indicate greater symptom severity\]. The number of participants achieving PASI-90 (defined as a 90% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.

    Time frame: Baseline (Day 1) and Week 8

  3. Number of Participants Achieving Psoriasis Area Severity Index 50 (PASI-50)

    The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The number of participants achieving PASI-50 (defined as a 50% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.

    Time frame: Baseline (Day 1) and Week 8

  4. Change From Baseline in Body Surface Area (BSA) Involved by Psoriasis

    The percentage of body surface area (BSA) covered by psoriatic lesions will be calculated. The BSA score represents the percentage of the patient's total body surface area affected by psoriasis. A negative change signifies clinical improvement.

    Time frame: Baseline (Day 1) and Week 8

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.

Of 15 phase 1/2 interventional studies under Psoriasis, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 10 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 3, 2026
StartActual
May 22, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07623486
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
May 22, 2026
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK44459

Start the discussion